"There is no evidence that insulin, however formulated, causes cancer," said Ulf Smith, MD, president of the European Association for the Study of Diabetes (EASD), and Edwin Gale, MD, editor of Diabetologia.

"There is no evidence of an overall increase in the rate of cancer development in patients on insulin glargine, and some suggestion that the risk may actually be reduced. There is no evidence of harm in type 1 diabetes or in premenopausal breast cancer."